NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
Clinical Trials
7 trialsNCT00500006 2015-01-30
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00123487 2014-11-03
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00872976 2013-07-22
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00101595 2011-04-14
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT00103701 2011-04-14
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT00298987 2010-02-08
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
Bristol-Myers Squibb
Phase 2 Completed